Clean intermittent catheterisation (CIC) of the bladder is used to imitate normal bladder emptying in patients with bladder dysfunction. CIC is associated with urinary tract infection (UTI) that may be difficult to treat in the case of antimicrobial resistance. The aim of this study was to establish the effect and safety of intravesical gentamicin treatment in such settings. In 2009, intravesical gentamicin treatment was started in selected patients. Here we describe our experience with two patients treated until March 2010. Two patients using CIC suffering recurrent UTI with multiresistant Escherichia coli were treated with daily administration of 80 mg intravesical gentamicin. On treatment they appeared asymptomatic. During 8-and 9month follow-up they were free of UTI, urine cultures were negative and there were no side effects. A systematic review was conducted through searches of PubMed and other databases. Clinical trials that met the eligibility criteria and displayed the efficacy or safety of intravesical aminoglycoside treatment in patients using CIC were studied. Study selection was performed by two independent reviewers. Eight studies were included for review. Owing to study heterogeneity, a meta-analysis could not be performed. Of four controlled studies using neomycin or kanamycin, two demonstrated a significant reduction in bacteriuria, whilst two other trials did not. One case series on neomycin/polymyxin showed that the majority of patients still developed bacteriuria. Three case series using gentamicin all pointed towards a significant reduction in bacteriuria and UTIs. There were no clinically relevant side effects reported but follow-up in all studies was limited. Although data are limited, intravesical treatment with gentamicin might be a reasonable treatment option in selected patients practicing CIC who suffer recurrent UTIs with highly resistant microorganisms.
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M a n u s c r i p t
Introduction
Clean intermittent catheterisation (CIC) of the bladder was introduced by Lapides in 1971 to manage children with neurogenic bladder dysfunction [1] . To date, this technique has become an important tool for the management of patients with bladder dysfunction. CIC will ideally be performed every 4-6 h, with the aim of mimicking normal emptying of the bladder and thus preventing overflow incontinence and dilatation of the upper urinary tract with potential loss of renal function. For patients requiring long-term or chronic catheterisation, CIC is considered the preferable method of urinary catheterisation since it is associated with less complications, in particular urinary tract infections (UTIs), compared with chronic indwelling bladder catheterisation [2] . However, even with CIC, colonisation of the bladder frequently develops as has been shown by the presence of significant bacteriuria in 61% of urine samples from patients practicing CIC [3] . Asymptomatic bacteriuria itself does not require antimicrobial treatment, but once symptoms occur it is considered to represent UTI, which is the major complication of CIC [4, 5] . Not surprisingly, recurrent UTI frequently occurs, requiring antimicrobial treatment that, in addition to the use of prophylactic antibiotics to prevent new episodes, supports the emergence of resistant organisms and further limits antimicrobial treatment options. In this respect, administration of intravesical gentamicin following CIC has the advantage of treating the site of infection with high local antibiotic concentrations [6] .
Here we report two patients practicing CIC suffering recurrent UTI due to multiresistant Escherichia coli. When other treatments had failed, these patients were eventually successfully treated with intravesical instillation of gentamicin. In addition, a systematic review was performed to evaluate the effectiveness and potential M a n u s c r i p t urinary catheterization. This search strategy was optimised for all consulted databases, taking into account the differences in the various controlled vocabularies as well as differences in database-specific technical variations (e.g. the use of quotation marks).
Study selection
Two reviewers (PLdE and CvN) independently determined study eligibility on the basis of the published abstracts; if eligible or indeterminate, the full article was retrieved for further review. Studies were excluded if they were reviews, editorials, guidelines, non-human studies or written in non-English language. All retrieved articles were discussed by the two reviewers and based on their consensus final selection for inclusion in the systematic review was made.
Data extraction
The following data were extracted from each study: M a n u s c r i p t
Statistical and microbiological methods
Although the aim was to perform a meta-analysis, the interventions evaluated in the selected studies were too heterogeneous, thus this was not feasible.
Interobserver agreement between the two reviewers with regard to study selection was assessed using the Cohen  test, in which a  value of 0.41-0.60 corresponds to fair agreement, 0.61-0.80 to good agreement, 0.81-0.92 to very good agreement and 0.93-1.00 to excellent agreement [7] .
Urine cultures were performed using standard microbiological methods, and resistance to antimicrobials was defined using European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria [8] .
Results
In 2009, intravesical treatment with gentamicin was started in selected patients practicing CIC who developed recurrent UTIs with a gentamicin-susceptible uropathogen but who otherwise had very limited treatment options. Here we describe our experience with two patients treated until March 2010. Computed tomography (CT) and ultrasonography of the urinary tract were normal. By exclusion, chronic bacterial prostatitis was diagnosed. Because he clinically responded well to self-treatment with SXT (960 mg twice a day), it was decided to continue this for 6 weeks as the urine culture turned negative; repeated semen culture still grew E. faecalis in the absence of bacteriuria. However, 2 weeks after a new episode of UTI developed with the same E. coli strain. For the next few months he was treated with prostatic massage combined with ceftriaxone, but this strategy appeared to be unsuccessful both clinically and microbiologically.
In an attempt to suppress the recurrent UTIs, it was decided to start treatment with 
Case 2
A 70-year-old female visited the outpatient clinic because of recurrent UTIs. Her medical history revealed type 2 diabetes mellitus, diabetic neuropathy and osteoarthritis leading to wheelchair-limited mobility. She had suffered from recurrent UTIs for more than 20 years, occasionally complicated by pyelonephritis. She was allergic to nitrofurantoin.
Ultrasonography revealed a post-void residual volume of 500 mL. Urodynamic evaluation demonstrated a neurogenic acontractile detrusor function that was ascribed to diabetic neuropathy [9] . She started to perform CIC four to six times daily.
During the next year she had frequent episodes of symptomatic UTI. Finally, she 
Study selection
The search strategy revealed 117 references. Of these, ten articles were selected for further review by one reviewer and nine by the other reviewer. Interobserver agreement between the reviewers was excellent, with a  value of 0.94 (P < 0.001).
After reviewing and discussing the ten articles, two articles were excluded: one article appeared to be a review that reported no original data [10] and the other article did A c c e p t e d M a n u s c r i p t not primarily assess the efficacy or safety of aminoglycoside bladder instillations [11] .
Details of the literature search and study selection are outlined in Fig. 1 .
Study characteristics
Characteristics of the included studies are presented in Table 1 . Overall, the level of evidence of all studies was limited. Five studies included hospitalised adult patients with newly diagnosed neurogenic bladder dysfunction requiring intermittent catheterisation in order to evaluate the prophylactic value of antibiotic bladder instillations in preventing bacteriuria [12] [13] [14] [15] 17] . The primary outcome assessed in these studies was the presence of significant bacteriuria. Either neomycin or kanamycin were the aminoglycosides of interest.
Two studies included children with neurogenic bladder and gentamicin bladder instillations [6, 18] . Both were case series that indicated a reduction of bacteriuria and UTI with intravesical gentamicin.
Finally, one study described case reports involving outpatient adult females with recurrent UTI [16] . All four patients were diagnosed with haemorrhagic cystitis and had a residual volume on urodynamic evaluation. CIC was started with gentamicin bladder instillations. There were no UTIs reported on treatment.
Efficacy of intravesical aminoglycoside
Because of the heterogeneous nature of the included studies and the lack of a comparative arm in most studies, performing a meta-analysis or data pooling was A c c e p t e d M a n u s c r i p t inappropriate. Therefore, the main outcomes of the individual trials are summarised in Table 1 .
In two trials with a control group, including a randomised controlled trial (RCT), aminoglycoside instillation of the bladder significantly reduced the incidence of bacteriuria [14, 15] . Another RCT and a retrospective case-control study could not demonstrate any difference in outcome [12, 17] .
In a prospective case series, all 10 children had sterile urine after 1 week of treatment, whereas E. coli was yielded in three of the urine cultures at baseline [6] .
Breakthrough UTI occurred in 26% of the children examined by Defoor et al. [18] . All those were on low-dose gentamicin (14.4 mg once daily), suggesting that a higher dosage of gentamicin is required to prevent UTI [18] .
Safety of intravesical aminoglycoside
Reports upon safety were scarce and poor. None of trials that investigated neomycin instillation presented details on drug toxicity or adverse effects. Pearman [14] stated that haematuria or other clinical evidence of chemical cystitis did not occur in any of the patients who received kanamycin/colistin instillations. None of the children investigated had detectable gentamicin serum levels [6, 18] . Small increases in serum creatinine levels were observed in 3 of 80 children evaluated by Defoor et al. [18] , but this was ascribed to underlying renal disease; no side effects, allergic reactions or clinical toxicities were documented.
Discussion
In this study, we demonstrated that intravesical gentamicin treatment was successful and safe in two patients practicing CIC who suffered from recurrent UTI. In one case it even suppressed chronic bacterial prostatitis. In addition, the systematic review summarises the available literature on the effectiveness and safety of intravesical aminoglycoside administration in patients practicing CIC.
The concept of intravesical drug delivery lies in the uroepithelium, a transitional epithelium lining the inner surface of the bladder. This layer is known to exhibit a tough barrier function that allows the instillation of potentially toxic drugs to achieve a localised pharmacological effect whilst avoiding systemic effects [19] . Diffusion of aminoglycosides across the uroepithelium is even more limited because of their polar cationic nature. Thus, by administrating aminoglycosides intravesically, high antimicrobial concentrations can be achieved with minimal concern of adverse effects such as nephrotoxicity or ototoxicity. Furthermore, it may thus prevent the development of antimicrobial resistance. Because in our patients the bladder was infected with a multiresistant E. coli, we opted to treat them intravesically with relatively high dosages of gentamicin to prevent further emergence of resistance.
Compared with previous studies, the dosage (80 mg) used was considerably higher [6, 16, 18] . This may have been overtreatment, but based on the literature review we can conclude that the optimal dosage remains unclear. However, even with the high dose used, no systemic absorption of gentamicin was observed as serum levels were repeatedly undetectable. This supports the hypothesis that systemic side effects are not to be expected.
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Neomycin was the first aminoglycoside to be administered directly into the bladder, initially to prevent bacteriuria in hospitalised patients with indwelling devices by means of continuous or intermittent irrigation [10] . However, this has not been advocated since Warren et al. [20] could not show any benefit in patients with indwelling catheters.
The review has some limitations that are predominantly related to the quantity, quality, design and heterogeneity of the original literature on this topic. In general, the few included studies had methodological flaws, the studies were heterogeneous and the sample sizes were small. Consequently, the evidence summarised in this review is not sufficient to draw definite conclusions on the effectiveness and safety of aminoglycoside instillations. As a tool to prevent bacteriuria in hospitalised patients, some benefit has been suggested but the results are not consistent [12, 14, 15] .
Furthermore, most studies included in this review did not differentiate between symptomatic and asymptomatic bacteriuria. The clinical relevance of intravesical aminoglycoside treatment therefore remains unclear in most of the studies. An exception might be the intravesical installation of gentamicin, as the three studies all point towards a significant reduction of bacteriuria and UTI in selected patients with recurrent UTI [6, 16, 18] . Combined with our own experience in two patients, we therefore consider intravesical gentamicin to be a reasonable treatment option in selected patients. This may contradict a recently published international guideline on the management of catheter-associated UTI [21] that recommends not using catheter irrigation with antimicrobials. However, this recommendation is predominantly based on studies in patients with a chronic indwelling urinary catheter in which intravesical installation of antimicrobials is more like a rinsing of the drainage bag and catheter M a n u s c r i p t rather than active treatment of bladder infection. In contrast, in our experience highdose gentamicin remained in the bladder for over 8 h per day when left following intermittent catheterisation; 80 mg gentamicin in 20 mL of normal saline (=4000 mg/L) was left in the bladder and, assuming a volume of 500 mL will be catheterised at the next catheterisation, the urine gentamicin level will still be 160 mg/L as was confirmed by Case 2. Therefore, we consider the potential development of antimicrobial resistance to be unlikely.
Regarding the safety of intravesical gentamicin, in 90 children reported in the literature there was no systemic absorption [6, 18] . Previously, negligible absorption of neomycin during post-operative irrigation through indwelling devices was reported [22] . However, caution is still warranted as two reports have noted neomycin ototoxicity following bladder irrigation through indwelling catheters [23, 24] .
Nevertheless, it should be emphasised that serum neomycin levels were not monitored whilst all these patients had end-stage renal disease. Moreover, there are no data on long-term follow-up of patients treated with intravesical aminoglycosides and one study suggested that it may disrupt the uroepithelium [25] . The duration of intravesical gentamicin treatment should therefore be determined based on an individual risk-benefit assessment.
In summary, we conclude that intravesical treatment with gentamicin appears to be safe and effective in treating and suppressing UTI in patients practicing CIC. In M a n u s c r i p t 1 
